Document Detail


Lacosamide in Refractory Mixed Pediatric Epilepsy: A Prospective Add-on Study.
MedLine Citation:
PMID:  22467791     Owner:  NLM     Status:  In-Data-Review    
Abstract/OtherAbstract:
Lacosamide is a new antiepileptic drug that is currently approved by the US Food and Drug Administration (FDA) for adults 17 years or older for partial-onset seizures. The authors reviewed 21 pediatric patients (<17 years) with various seizure types who were started on oral lacosamide as part of a prospective add-on study as adjunctive therapy for refractory epilepsy. Five patients were excluded due to less than 3 months of meaningful follow-up. Maintenance dosages used ranged from 2.4 to 19.4 mg/kg/d. Eight of 16 (50%) patients had greater than 50% reduction in seizure frequency with adjunctive lacosamide therapy. Eight (50%) patients had generalized epilepsy including 4 with Lennox-Gastaut syndrome. Lacosamide was effective therapy for most seizure types but was particularly effective for partial-onset seizures. Lacosamide was effective in treating 5 of 8 (62.5%) localization-related epilepsies but only 2 of 8 (25%) generalized epilepsies, both Lennox-Gastaut syndrome patients with greater than 90% seizure reduction. None of these very refractory patients remained seizure free.
Authors:
Reena Gogia Rastogi; Yu-Tze Ng
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Journal of child neurology     Volume:  27     ISSN:  1708-8283     ISO Abbreviation:  J. Child Neurol.     Publication Date:  2012 Apr 
Date Detail:
Created Date:  2012-04-02     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8606714     Medline TA:  J Child Neurol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  492-5     Citation Subset:  IM    
Affiliation:
1Division of Pediatric Neurology, Barrow Neurological Institute, Phoenix, AZ, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Transcription activation by NtcA in the absence of consensus NtcA-binding sites in an anabaena heter...
Next Document:  Comparison of exposure estimates in the Finnish job-exposure matrix FINJEM with a JEM derived from e...